Year: 2024

Care Walk 2024 Location Directory

Here are a list of Care Walk Locations! Care Walk is the Cooley’s Anemia Foundation’s annual fundraising event and opportunity to bring together the thalassemia community and its supporters around the country. Funds raised support medical research to fight thalassemia, a genetic blood disorder, as well as patient support services for thalassemia patients across the country. Your Walk, Your Way, […]

Read more


Registration Now Open for 2024 Patient-Family Conference

The Cooley’s Anemia Foundation is pleased to announce that the 2024 Patient-Family Conference will be held from July 12-14 at the Renaissance Concourse Atlanta Airport Hotel. During registration, you will have the option to choose whether you would like to attend in person or virtually. If you choose to attend virtually, only the sessions on […]

Read more


Thalassemia Care Walk 2024 – Information

Care Walk is the Cooley’s Anemia Foundation’s annual fundraising event and opportunity to bring together the thalassemia community and its supporters around the country. Funds raised support medical research to fight thalassemia, a genetic blood disorder, as well as patient support services for thalassemia patients across the country. Click here to register for Care Walk!! […]

Read more


FDA Approves Vertex & CRISPR’s Gene Editing Therapy to treat Beta Thalassemia

Treat Beta Thalassemia

The FDA has approved Vertex and CRISPR’s gene-editing therapy Casgevy to treat beta thalassemia. Casgevy becomes the first therapy for the rare blood disorder to use the innovative CRISPR gene-editing technology. Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing therapy Casgevy (exa-cel) to treat transfusion-dependent beta thalassemia (TDT). The approval […]

Read more


Agios Pharmaceuticals Announces Phase 3 ENERGIZE – Treatment for Thalassemia Patients

Phase 3 ENERGIZE

Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia January 3, 2024 – Agios Pharmaceuticals, Inc. today announced that the global Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary endpoint of […]

Read more


Secured By miniOrange